Besufetamig

{
  "id": "MLC-T-ONC-011962",
  "term": "Besufetamig",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the T-cell surface antigen CD3, with potential immunomodulatory and antineoplastic activities. Upon administration, besufetamig binds to both PD-1 expressed on activated T and B cells and certain malignant T cells and CD3 antigen on cytotoxic T lymphocytes (CTLs). This may activate and redirect CTLs to PD-1-expressing cells, resulting in CTL-mediated killing of these cells. This may lead to anti-tumor activity in some T-cell lymphomas, and immunomodulatory activity in some autoimmune diseases.",
  "synonyms": [
    "anti-PD-1/CD3 bispecific antibody ONO-4685",
    "PD-1 x CD3 bispecific antibody ONO-4685"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/besufetamig/"
}